MiniMed Group Shares Surge 14% Over Strong Revenue Growth In Q4

MiniMed (NASDAQ: MMED) said it expanded its agreement with Abbott to commercialize integrated dual glucose-ketone sensors for exclusive use with MiniMed smart dosing systems. The sensors, built on the Instinct platform, aim to detect rising ketones earlier to help reduce diabetic ketoacidosis risk. Abbott’s dual system has CE Mark and is under FDA review; further milestones are expected.

MiniMed (Nasdaq: MMED) reported Q4 net sales of $837 million, up 15.6% reported and 8.7% organic, and full FY26 net sales of $3.102 billion, up 14.2% reported and 8.0% organic, according to the company. It cited FDA clearance for MiniMed Flex and CE Mark for Instinct, plus global launch of MiniMed Go. For FY27, it expects ~10% organic revenue growth and ~16% adjusted EBITDA margin.

Keybanc analyst Sophie Karp initiated coverage on NiSource Inc. (NYSE: NI) with an Overweight rating and a price target of $52. Additionally, BTIG analyst Marie Thibault began coverage on Minimed Group, Inc. (NASDAQ: MMED) with a Buy rating and a $25 price target, and HC Wainwright & Co. analyst Yi Chen initiated coverage on Envoy Medical, Inc. (NASDAQ: COCH) with a Buy rating and a $2.5 price target. These inaugurate Tuesday's top analyst initiations, reflecting bullish outlooks for the respective companies.

Vera Bradley reported first-quarter FY2027 results, with consolidated net revenues up 7.8% to $55.7 million. The company posted a $4.8 million net loss from continuing operations ($0.17/share) and a non-GAAP net loss of $2.5 million ($0.09/share), versus prior-year losses of $18.3 million. Gross margin rose to 51.8% from 44.1%, and operating loss narrowed to $4.6 million. Vera Bradley expects non-GAAP operating loss improvement of at least 50% year over year and FY2027 sales of $255–$270 million

Navan (NAVN) shares rose about 16–17% in premarket after the travel and expense platform reported a narrower Q1 net loss and raised its FY27 outlook. Net loss fell to $20.51M ($0.08/share) from $61.26M ($1.33) a year earlier. Revenue grew 40% to $220.23M; Gross Booking Volume rose 50% to $3.1B. Navan now expects FY27 revenue of $907M–$913M (vs $866M–$874M) and adjusted operating income of $76M–$80M (vs $58M–$62M).

SailPoint’s Q1 2027 earnings call highlighted demand for unified governance as nonhuman identities grew 40% of identity growth in Q1. Management said migration-driven ARR more than doubled year over year and the Agentic pipeline doubled. Full-year guidance assumes 90%–95% of net new ARR from SaaS, plus a 10% annual migration rate of $350M on-prem ARR.